AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Black Diamond Therapeutics shares surge 15.25% after-hours after announcing Phase 2 silevertinib trial data webcast.
ByAinvest
Tuesday, Dec 2, 2025 4:18 pm ET1min read
Black Diamond Therapeutics surged 15.25% in after-hours trading following the announcement of a webcast scheduled for December 3, 2025, to present Phase 2 clinical trial results for silevertinib and provide an oncology program update. The company highlighted silevertinib’s potential as a fourth-generation EGFR inhibitor targeting EGFR-mutant non-small cell lung cancer and glioblastoma, emphasizing its brain-penetrant properties and ability to address resistance mechanisms. The event, accessible via the investor relations section of its website, generated immediate investor optimism about the drug’s therapeutic potential and pipeline progress. Other news, including price target adjustments and restructuring updates, were either older or unrelated to the after-hours rally. The webcast announcement directly aligned with the stock’s sharp rise, reflecting market anticipation of positive clinical data.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet